% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Galldiks:877691,
author = {Galldiks, Norbert and Lohmann, Philipp and Langen,
Karl-Josef},
title = {{I}maging challenges following newer treatment options:
{A}re companion diagnostics required in neurooncology?},
journal = {Expert review of molecular diagnostics},
volume = {20},
number = {7},
issn = {1744-8352},
address = {Abingdon},
publisher = {Taylor $\&$ Francis Group},
reportid = {FZJ-2020-02401},
pages = {651-652},
year = {2020},
abstract = {Contrast-enhanced MRI is the method of choice for follow-up
imaging in patients with brain tumors, but its specificity
is low despite outstanding spatial resolution [1,2].
Importantly, the differentiation of treatment-related
changes from actual tumor progression following newer
treatment options such as immunotherapy using checkpoint
inhibitors or vaccines is challenging by anatomical MRI
alone [2–4]. Specifically, inflammation with intratumoral
T-cell infiltrates triggered by immunotherapy may lead to
highly variable MR imaging findings including contrast
enhancement that may suggest tumor progression. Moreover,
neuroimaging changes induced by these treatment options may
also hamper a reliable response assessment.},
cin = {INM-3 / INM-4},
ddc = {570},
cid = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406},
pnm = {572 - (Dys-)function and Plasticity (POF3-572)},
pid = {G:(DE-HGF)POF3-572},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:32552245},
UT = {WOS:000549555100001},
doi = {10.1080/14737159.2020.1782191},
url = {https://juser.fz-juelich.de/record/877691},
}